Inspire sleep apnea is an FDA-approved implantable neurostimulator that stimulates the hypoglossal nerve to prevent airway obstruction during sleep. First approved by the FDA in 2014, Inspire is the only FDA-approved implant for obstructive sleep apnea. It has been used by more than 100,000 patients worldwide.
Inspire delivers a 79% reduction in sleep apnea events at 5 years and a 93% patient recommendation rate. Candidates must have an AHI of 15 to 100, a BMI at or below 40, and documented CPAP failure. Surgery is a 2-to-3-hour outpatient procedure with a 4-week recovery before device activation. Battery life on the newest Inspire models reaches 11 years.
Serious complications occur in fewer than 1% of procedures. About one-third of patients don’t achieve the target 50% AHI reduction. Insurance typically covers Inspire after an appeal. This review covers eligibility, results, risks, costs, and whether Inspire is the right choice.
What Is Inspire Sleep Apnea?
Inspire sleep apnea is an FDA-approved implantable neurostimulator that delivers mild electrical impulses to the hypoglossal nerve to keep the airway open during sleep. First approved by the Food and Drug Administration in 2014, it remains the only FDA-approved implant for obstructive sleep apnea. The system works entirely inside the body. No external mask or hose is required.
Here’s the thing: Inspire doesn’t just mask the symptoms of sleep apnea. It targets the root cause. When the airway collapses during sleep, the brain receives less oxygen. This triggers repeated awakenings throughout the night. Inspire prevents that cycle by keeping the airway structurally open with each breath.
The Inspire impulse generator closely resembles a cardiac pacemaker in both size and design. Inspire Medical Systems, Inc., headquartered in Golden Valley, Minnesota, developed the device. The latest Inspire implant model is MRI compatible under specific conditions outlined in the device manual.
Who Is Inspire Sleep Apnea For?
Inspire sleep apnea is designed for adults aged 22 and older with moderate to severe obstructive sleep apnea who can’t tolerate or get consistent benefit from CPAP therapy. The device is also approved for adults aged 18 to 21 with moderate to severe OSA and for pediatric patients aged 13 to 18 with Down syndrome who meet additional criteria. All candidates must have documented CPAP failure or intolerance.
Eligible patients must have an apnea-hypopnea index (AHI) of 15 to 100. Patients must not be significantly obese, with a BMI at or below 40. PAP failure is defined as an AHI above 15 despite therapy use. PAP intolerance means the patient uses it fewer than 5 nights per week or returns the machine after attempting use.
An Inspire-trained physician evaluates overall health and examines the airway before approval. Drug-induced sleep endoscopy (DISE) is required to confirm eligibility. Patients with complete concentric collapse at the soft palate level are excluded, because tongue protrusion won’t resolve that type of obstruction.
The Inspire system consists of three implanted components — an implantable pulse generator (IPG), a stimulation lead, and a sensing lead — paired with an external physician programmer and a patient remote. The IPG is the central component that delivers stimulation based on the patient’s breathing rhythm. The physician programmer allows the doctor to adjust settings at follow-up appointments.
Key Components:
- Implantable pulse generator (IPG): placed under the skin in the upper chest
- Stimulation lead: attached to the branch of the hypoglossal nerve
- Sensing lead: placed between intercostal muscles to detect breathing
- Patient remote: small handheld device used to turn therapy on and off
- Inspire app: tracks sleep goals and allows direct data sharing with the provider
The patient remote is small enough to fit in a carry-on bag. No mask, hose, or bulky equipment travels with the patient. The Inspire app connects to the remote and provides sleep data directly to the treating physician.
How Does Inspire Sleep Apnea Work?
Inspire sleep apnea works by having the sensing lead detect the patient’s breathing rhythm and signal the IPG to send mild electrical stimulation to the hypoglossal nerve, which moves the tongue forward to keep the airway open with each breath. This process is synchronized with the patient’s natural breathing pattern throughout the night. The stimulation strength is adjustable and shouldn’t be painful or uncomfortable.
In plain English: the hypoglossal nerve controls the genioglossus muscle. That muscle is the primary gatekeeper for airway patency during sleep. Stimulating it with small electrical impulses prevents the tongue from blocking the airway. The impulse is tuned to each patient’s needs over the weeks following activation.
Inspire represents a fundamentally different approach from CPAP. CPAP forces pressurized air through a mask to keep the airway open. Inspire activates the muscles that naturally hold the airway open. Patients typically feel only a mild tingling sensation or gentle contraction in the tongue during adjustment. Does that sensation bother people? Most adjust within weeks, and the stimulation becomes unnoticeable during sleep.
What Does the Inspire Implant Do While You Sleep?
The Inspire implant delivers gentle electrical pulses to the hypoglossal nerve with each breath the patient takes. This stimulation results in a slight forward displacement of the tongue that maintains airway patency throughout the night. The sensing lead continuously monitors the patient’s breathing rhythm. When inspiration is detected, the IPG fires a stimulation signal through the lead attached to the hypoglossal nerve branch.
Here’s what actually happens in people with OSA: the tongue and soft palate relax during sleep and collapse into the airway. This reduces oxygen delivery to the brain. The brain triggers a brief awakening to restore breathing. That cycle can repeat dozens or even hundreds of times per night. Inspire breaks it before it starts.
The stimulation level is adjustable through the patient remote. Patients self-titrate the setting over a limited range during the first month after activation. A formal titration sleep study occurs approximately two months after implantation to optimize final stimulation parameters.
The Inspire device is controlled through a small handheld remote that patients turn on before sleep and off upon waking, with the option to adjust stimulation strength or pause therapy during the night if needed. No machine setup, mask fitting, or hose connection is required. The remote is the only piece of equipment a patient needs at home or while traveling.
The Inspire app provides additional control and monitoring. The app tracks sleep goals and lets patients share data directly with their physician. Data from the device is reviewed during follow-up visits without the need for additional testing or equipment.
Physicians can also adjust stimulation settings using the external physician programmer at follow-up appointments. Adjustments are based on the patient’s reported experience and sleep study data. Patients are encouraged to use the device every single night for best results.
Who Qualifies for Inspire Sleep Apnea Treatment?
Inspire sleep apnea treatment is indicated for patients aged 22 and older with an AHI of 15 to 100 who have failed or cannot tolerate positive airway pressure therapy, as confirmed by a trained physician and drug-induced sleep endoscopy. PAP failure is defined as an inability to eliminate OSA with an AHI above 15 despite use. PAP intolerance covers patients who use it fewer than 5 nights per week or those who return the machine after attempting use.
Inspire Sleep Apnea Eligibility Requirements:
| Criterion | Requirement |
|---|---|
| Age | 22 years or older (18-21 with specific OSA criteria) |
| AHI range | 15 to 100 events per hour |
| BMI | 40 or below |
| CPAP status | Documented failure or intolerance |
| Anatomical screen | No complete concentric retropalatal collapse on DISE |
Candidates must not have complete concentric collapse at the soft palate level. This finding is identified through DISE, a specialized procedure performed by trained specialists. It’s a required step before Inspire surgery is scheduled. What happens if you fail DISE? Patients with complete retropalatal collapse are disqualified — and this protects them from a procedure that won’t work.
Patients must also not have central or mixed apneas exceeding 25% of total AHI. Pregnant patients are excluded from Inspire treatment. Patients who can’t operate the sleep remote are not candidates for the therapy.
What BMI Is Required for Inspire Sleep Apnea?
Inspire sleep apnea now accepts candidates with a BMI up to 40, following an expanded FDA approval issued in June 2023 that raised the upper BMI limit from 32 to 40, significantly broadening access for patients with higher body weight. The original STAR trial enrolled patients with a BMI at or below 32. Data from the ADHERE Registry later showed that patients with a BMI up to 40 achieved outcomes consistent with the original trial results.
BMI measures body fat based on height and weight. A normal BMI range is 18.5 to 24.9. A BMI above 30 is classified as obese. The updated Inspire criteria now include patients in the class 2 obesity range, defined as a BMI between 35 and 40.
Patients with a BMI above 40 have not been studied and remain excluded from Inspire therapy. Weight loss before evaluation may help borderline candidates meet the BMI requirement. An Inspire-trained physician makes the final eligibility determination at the consultation appointment.
Does Insurance Cover Inspire Sleep Apnea?
Yes. Insurance coverage for Inspire sleep apnea is available through most commercial insurers, though initial requests are typically denied and must be appealed with documentation of CPAP failure to succeed. Government insurance coverage through Medicare and Medicaid varies by plan and state. Establishing coverage often results in a delay between the eligibility determination and the scheduled surgery date.
The good news? Most patients with legitimate candidacy succeed in obtaining coverage after appeal. Documentation of CPAP failure or intolerance, sleep study results, and the DISE report are the primary evidence points for a successful appeal. Working with an Inspire-trained physician’s office improves the chance of approval.
Cost without insurance can be substantial for a surgical device implantation procedure. Inspire Medical Systems provides Inspire Therapy Advisors to help patients understand coverage options. Patients are encouraged to verify coverage details with their insurer before scheduling a consultation.
What Happens During the Inspire Sleep Apnea Procedure?
The Inspire sleep apnea procedure is a same-day outpatient surgery under general anesthesia that uses three small incisions to place the IPG in the chest, the stimulation lead at the hypoglossal nerve, and the sensing lead between the intercostal muscles. The first incision is made in the upper right chest to house the IPG. A second incision is made just under the chin where the hypoglossal nerve is located. A third incision along the side of the chest positions the sensing lead.
Procedure Steps:
- The patient undergoes general anesthesia in an outpatient surgical setting.
- Three small incisions are made at the upper chest, under the chin, and along the side of the chest.
- The IPG is placed under the skin in the chest pocket.
- The stimulation lead is tunneled to the hypoglossal nerve branch.
- The sensing lead is placed between the intercostal muscles to detect breathing.
- The incisions are closed and most patients return home the same day.
Most patients take over-the-counter pain medications as needed during recovery. The device isn’t activated immediately after surgery. Activation occurs approximately four weeks post-surgery, once the incision sites have fully healed. Why wait 4 weeks? The delay allows leads to stabilize in position before stimulation begins, improving long-term efficacy.
Inspire surgery typically takes 2 to 3 hours from start to finish and is performed as an outpatient procedure, meaning most patients go home the same day without an overnight hospital stay. The procedure is done under general anesthesia. Over-the-counter pain medications are generally sufficient for managing post-operative discomfort.
Worth knowing: serious complications from Inspire surgery are very rare. Fewer than 1% of patients experience major complications from the procedure. The largest real-world Inspire study found that 99.6% of procedures were completed without any major adverse events.
Bruising and temporary tongue tingling are the most commonly reported post-surgical effects. Both typically resolve within weeks in most patients. Surgeons advise planning a short recovery period before returning to normal daily activities.
What Is Recovery Like After Inspire Sleep Apnea?
Recovery after Inspire sleep apnea surgery involves a 4-week healing period before device activation, followed by a formal titration sleep study approximately two months post-implantation to set final stimulation parameters. Patients return for a follow-up appointment about one month after surgery for device education and initial activation. The healing period allows the leads to stabilize in their anatomical positions.
During the first month after activation, patients slowly self-titrate the stimulation level within a limited range. This step allows the body to adjust to the sensation of tongue muscle contraction during sleep. Polysomnography occurs at approximately two months post-implantation to formally set final stimulation settings.
And it gets better: once fully titrated, the system runs automatically with every breath during sleep. The newest Inspire batteries last 11 years before replacement is needed. Inspire Medical Systems continues to advance device technology, including battery life improvements based on patient and physician feedback.
What Are the Benefits of Inspire Sleep Apnea?
Inspire sleep apnea delivers a 79% reduction in sleep apnea events at 5 years, a 90% rate of bed partners reporting no or soft snoring, and a 93% patient recommendation rate, according to the STAR trial outcomes published by Woodson and colleagues in 2018. Real-world clinical studies also show significant quality-of-life improvements, with Inspire patients outperforming untreated controls over a 3-month period. The therapy eases anxiety and supports higher activity levels.
Proven Benefits of Inspire Sleep Apnea:
- 79% reduction in sleep apnea events at 5 years (STAR trial, Woodson et al., 2018)
- 90% of bed partners report no snoring or soft snoring
- 93% of patients recommend Inspire to a friend or family member
- 91% of patients prefer Inspire over CPAP
- Significant quality-of-life improvements confirmed at 3-month real-world follow-up
Bottom line: CPAP requires ongoing masks, filters, hoses, and distilled water. Inspire requires only the patient remote. The difference in daily maintenance is substantial. Travel becomes as simple as dropping a remote in a carry-on bag rather than checking a CPAP machine.
Dr. Chen of Cleveland Clinic notes that Inspire patients have ‘less maintenance on their part than with CPAP.’ Patient accounts reinforce this consistently. The freedom from wearing a mask is cited as the single most impactful aspect of switching to Inspire therapy. Is that freedom worth a surgical procedure? For the 91% who prefer Inspire over CPAP, the answer is clearly yes.
Does Inspire Sleep Apnea Actually Reduce Apnea Events?
Yes. Inspire sleep apnea has produced a median AHI reduction from 33 events per hour to 10 events per hour at 12 months, with an oxygen desaturation index (ODI) reduction of 70% over the same period, placing most patients in the mild OSA range following therapy. These results come from clinical studies reviewed by Drugs.com and the 5-year STAR trial data. The STAR trial confirms sustained efficacy at the five-year mark.
Success rates are reported at 72 to 75% at both one and five years post-implantation. In the primary Inspire-funded study, two-thirds of participants saw sleep apnea events reduced by at least 50% at 12 months. The typical sleep apnea score fell from the moderate range into the mild range. Is mild OSA still clinically significant? Yes, but it carries far lower cardiovascular and cognitive risk than moderate or severe OSA.
Here’s the part most people miss: about one-third of Inspire patients don’t achieve that 50% threshold. These non-responders must return to CPAP or other treatments. The device is generally left in place even then, to avoid risking damage to the hypoglossal nerve during removal.
Is Inspire Sleep Apnea Better Than CPAP?
Yes. Inspire sleep apnea is preferred over CPAP by 91% of patients who’ve used both therapies, according to Inspire Medical Systems data on file, and produces quality-of-life improvements significantly greater than those seen in untreated OSA patients over a 3-month period. Bed partners of Inspire users report no snoring or soft snoring at a rate of 85 to 90%. The 93% patient recommendation rate is among the highest in OSA treatment research.
To be clear: CPAP remains the clinical gold standard for OSA treatment. Adequate CPAP adherence is defined as use for more than 4 hours per night on at least 5 nights per week. Many patients find that level of consistency difficult to maintain over the long term — which is precisely why Inspire exists.
Dr. Chen reports less maintenance burden for Inspire patients than for CPAP users. The 11-year battery life on the newest Inspire models further reduces long-term device management. Physicians strongly recommend exhausting CPAP options before pursuing any surgical alternative.
What Do Inspire Sleep Apnea Reviews Say?
Inspire sleep apnea reviews are overwhelmingly positive, with 83.7% of patients awarding 5 stars and 12.3% awarding 4 stars on RealPatientRatings, for a combined 96% positive rating across 454 verified patient reviews. More than 100,000 people with obstructive sleep apnea have chosen Inspire therapy. The 93% patient recommendation rate reflects high satisfaction among those who’ve completed treatment.
Patient Rating Breakdown:
| Rating | Count | Percentage |
|---|---|---|
| 5 Stars | 380 | 83.7% |
| 4 Stars | 56 | 12.3% |
| 3 Stars | 11 | 2.4% |
| 2 Stars | 6 | 1.3% |
| 1 Star | 1 | 0.2% |
Research from the National Council on Aging (NCOA Adviser) identifies Inspire as a promising option for patients who can’t tolerate CPAP. The NCOA review highlights real quality-of-life gains with lasting results. Drugs.com describes Inspire as a ‘surgical, FDA-approved alternative’ for those who struggle with CPAP discomfort over the long term.
What Positive Results Do Patients Report?
Patients report meaningful improvements in energy, emotional health, and personal relationships after starting Inspire sleep apnea therapy, with many describing a feeling of returning to themselves after years of poor-quality sleep. Monica Rosco, featured by Cleveland Clinic, reports more energy, better stress management, and heavier, more restful sleep. She traveled to Europe for her 25th wedding anniversary without bringing a CPAP machine.
Bed partner satisfaction is one of the most frequently cited benefits. A 90% bed partner rate of reporting no or soft snoring reflects genuine sleep quality improvement for both the patient and their partner. Many patients describe freedom from a mask as the single most impactful change in their daily lives.
Inspire’s own patient ambassador program features real accounts from patients describing their journey from CPAP struggle to consistent restful sleep. Life with Inspire therapy is described as ‘feeling like themselves again.’ Dr. Chen’s patients with moderate to severe sleep apnea are consistently described as ‘very happy with their treatment.’
What Are the Common Complaints About Inspire?
The most common complaint about Inspire sleep apnea is post-surgical recovery pain, with some patients describing significant head and neck discomfort during the first days or weeks after implantation that goes beyond typical surgical recovery. One patient described the recovery as ‘a nightmare’ with ‘terrible pain in my head and neck.’ This level of discomfort isn’t universal, but surgeons discuss it with candidates during pre-surgical evaluation.
Non-response is the other major concern. About one-third of Inspire patients don’t see a 50% or greater reduction in sleep apnea events at 12 months. These patients must return to CPAP or pursue other treatments. The Inspire device is generally left in place even when therapy fails, to protect the hypoglossal nerve from removal damage.
The adjustment period after activation can also be frustrating. Self-titrating stimulation levels over the first month requires patience and consistency. Some patients describe the transition from CPAP as ‘awkward’ before they adapt to the sensation of tongue stimulation during sleep.
What Are the Side Effects of Inspire Sleep Apnea?
Inspire sleep apnea most commonly causes temporary bruising and tingling along the tongue during the weeks immediately following the procedure, both of which resolve without medical intervention in most patients. Patients may also feel a mild tingling sensation or gentle muscle contraction in the tongue during device use at night. The stimulation level is adjustable to minimize discomfort during the adjustment period. Does stimulation keep patients awake? No — most patients sleep through it after a short adjustment period of days to weeks.
Serious complications are rare. Fewer than 1% of patients experience major complications from the Inspire procedure. The largest real-world study found that 99.6% of Inspire procedures were completed successfully without major adverse events, according to ADHERE Registry data.
MRI compatibility depends on the specific Inspire model in place. Patients with Model 3024 cannot undergo MRI. Patients with Model 3028 can undergo MRI if the conditions in the ‘MRI Guidelines for Inspire Implant’ manual are met. All treating physicians should be informed of the implant before any imaging is scheduled.
Who Should Avoid Inspire Sleep Apnea Treatment?
Inspire sleep apnea treatment is contraindicated for patients with complete concentric collapse at the soft palate level, because tongue protrusion cannot resolve this pattern of airway obstruction, making the device clinically ineffective for this group. This finding is identified through DISE before surgery is approved. Patients with this anatomical pattern are excluded at the screening stage.
Contraindications for Inspire Sleep Apnea:
- Complete concentric collapse at the soft palate level
- Central or mixed apneas exceeding 25% of total AHI
- Any condition compromising neurological control of the upper airway
- Pregnancy or plans to become pregnant
- Inability to operate the sleep remote
- BMI above 40
Pediatric patients with Down syndrome and a BMI above the 95th percentile on CDC neurotypical growth curves have not been studied. The thorough pre-surgical evaluation process, including DISE, exists to ensure only appropriate candidates proceed to implantation.
How Much Does Inspire Sleep Apnea Cost?
Inspire sleep apnea involves costs associated with surgical implantation and device hardware, making insurance coverage critical for most patients, and the appeal process for commercial insurers is typically successful for qualified candidates who document CPAP failure. Out-of-pocket costs without insurance can be substantial given the surgical nature of the procedure. Most commercially insured patients can access coverage after a successful initial denial appeal.
Compared to CPAP, Inspire carries lower long-term supply costs. CPAP requires ongoing purchases of masks, tubing, filters, and humidifier water over years of use. Inspire requires only the patient remote after implantation. The newest Inspire batteries last 11 years, limiting long-term maintenance costs significantly.
Inspire vs CPAP — Long-Term Cost Factors:
- Inspire: one-time surgical procedure plus device; no ongoing supply costs
- CPAP: machine purchase plus annual mask, tubing, filter, and humidifier water costs
- Inspire battery life: up to 11 years before replacement required
- CPAP masks: typically replaced every 3-6 months
- Insurance: both are usually covered, but Inspire requires appeal in most cases
Inspire Medical Systems provides Inspire Therapy Advisors to help patients understand coverage options and connect with Inspire-trained physicians. Patients are encouraged to contact an advisor before scheduling a consultation. Verifying coverage details with the insurer before surgery is strongly recommended.
Is Inspire Sleep Apnea Worth the Price?
Yes. Inspire sleep apnea delivers lasting quality-of-life improvements with no ongoing supply costs and an 11-year battery life, all confirmed by 5-year STAR trial outcomes and ADHERE Registry real-world data. Dr. Chen calls his Inspire patients ‘very happy with their treatment.’ The NCOA Adviser rates Inspire a ‘great fit’ for CPAP-intolerant patients seeking a minimally invasive OSA solution.
Research confirms sustained efficacy through 5 years of follow-up. The benefits aren’t short-lived. Quality-of-life gains include improved daytime energy, better emotional well-being, and stronger personal and professional relationships. These are documented outcomes from both clinical trials and real patient accounts.
That said, the equation changes for non-responders. Patients who don’t achieve a clinical response face the costs of surgery and recovery without improved sleep. Proper patient selection is the key variable separating an excellent outcome from a poor one.
Is Inspire Sleep Apnea FDA Approved?
Yes. Inspire sleep apnea received initial FDA approval in 2014 and remains the only FDA-approved implantable device for obstructive sleep apnea, with an expanded approval issued in June 2023 that broadened eligibility to include AHI up to 100 and BMI up to 40. The original approval was based on outcomes from the STAR trial. The 2023 expansion allowed patients with higher AHI values and higher BMI to access the therapy.
Inspire Medical Systems has maintained FDA approval status for over a decade. The ADHERE Registry, an ongoing real-world observational study, continues to generate post-market evidence supporting Inspire’s effectiveness in broader populations. More than 100,000 patients worldwide have received Inspire therapy under FDA approval.
The device is classified as a Class III medical device, the highest level of FDA oversight. What does Class III mean for patients? It means Inspire underwent the most rigorous pre-market review process the FDA requires before approval. Patients can review the Summary of Safety and Effectiveness Data (SSED) published on the FDA’s official website. The approval letter for the June 2023 expansion is also publicly available through FDA records.
Is Inspire Sleep Apnea the Only FDA-Approved Implant for OSA?
Yes. Inspire sleep apnea is currently the only FDA-approved implantable device for obstructive sleep apnea, a distinction it has held since its original approval in 2014, with another competitive device still undergoing clinical trials as of 2025. The Inspire Upper Airway Stimulation system received its PMA (Premarket Approval) from the FDA on the basis of clinical trial data demonstrating reasonable assurance of safety and effectiveness. No other implantable OSA device has yet reached this approval milestone.
This monopoly on FDA-approved OSA implants gives Inspire a unique position in the treatment landscape. Patients who cannot tolerate CPAP and are not candidates for other surgical options — such as UPPP or jaw advancement surgery — have Inspire as their primary implantable alternative. This status is reflected in the growing number of Inspire-trained physicians and implanting centers nationwide.
Inspire Medical Systems continues to invest in next-generation device development. The FDA approved the Inspire V therapy system in 2024, according to the American Academy of Sleep Medicine. Each new system generation aims to improve sensing accuracy, stimulation efficiency, and patient comfort.
Is Inspire Sleep Apnea Worth It?
Yes. Inspire sleep apnea is worth it for properly selected candidates, with success rates of 72 to 75% at one and five years, a median AHI drop from the moderate to the mild range, and quality-of-life improvements confirmed by multiple independent studies. In patients who meet all eligibility criteria and achieve a clinical response, Inspire delivers sleep apnea control comparable to CPAP. The therapy is not appropriate for every patient with OSA.
Proper patient selection is the single most important factor. Patients who truly can’t tolerate CPAP, who meet the AHI and BMI criteria, and who don’t have complete retropalatal concentric collapse are the best candidates. In this group, the device performs at its best. Outcomes outside this profile are less predictable. What’s the risk if it doesn’t work? The device stays in place and patients return to CPAP — no net loss in treatment options, but surgery costs are real.
The NCOA Adviser calls Inspire a ‘promising option’ for CPAP-intolerant patients with moderate to severe OSA. Research confirms real quality-of-life improvements with lasting results. For the right candidate, Inspire represents a meaningful, sustained improvement in sleep health and overall well-being.
Should You Choose Inspire Over CPAP?
No. Inspire sleep apnea is not a replacement for CPAP but a surgical alternative specifically for patients with documented CPAP failure or intolerance, as CPAP remains the clinical gold standard for obstructive sleep apnea treatment. Physicians recommend ensuring patients truly cannot tolerate CPAP before pursuing any surgical option. The decision to move forward with Inspire should follow genuine, sustained attempts to succeed with CPAP therapy.
For patients who can’t sustain CPAP use, Inspire offers a clinically validated, FDA-approved alternative. The 91% preference rate for Inspire over CPAP reflects high satisfaction among patients who were unable to make CPAP work long-term. Inspire is the only FDA-approved implantable option currently available for OSA.
So, is Inspire right for you? That answer requires a consultation with an Inspire-trained physician and a full evaluation, including DISE. Patients who pass all eligibility criteria have the best chance of achieving the clinical outcomes reported in published trials. Don’t skip the screening — it exists specifically to protect you from a procedure that won’t work.